Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Comanche Biopharma
This study will involve female subjects meeting all inclusion criteria and no exclusion criteria. Cohorts of CBP-4888 are planned to be investigated in a sequential dose-escalation manner. Each cohort of subjects will be randomized to CBP-4888 to placebo and administered a single subcutaneous dose.
Age
18–50
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Healthy non-pregnant female subjects
Body mass index (BMI) ≥ 18.5 and ≤ 35.0 kg/m2
Medically healthy, defined as having no clinically significant abnormal screening results including clinical laboratory evaluations, medical history, vital signs, ECG, and physical examination as deemed by the Investigator.
You may not be if
Screening blood pressure \< 100/60 mmHg or \> 140/90 mmHg
Screening heart rate that is \< 40 bpm or \> 99 bpm
Clinically significant ECG abnormality at screening
Used prescription medication within 14 days prior to dosing
Used over the counter (OTC) medications (including herbal products, nutritional supplements, dietary supplements, and/or vitamins) within 7 days prior to dosing
Donated blood or had significant blood loss within 56 days prior to dosing
